Please assess the completion status of the following clinical trial:

Trial Title: Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Provided written informed consent.~* Diagnosed with primary RLS using the International RLS Study Group Diagnostic Criteria with a total score of 15 or greater on the International RLS (IRLS) Rating Scale and significant sleep disturbance indicated on Item 4 of the IRLS rating scale.~* Have history of RLS symptoms at least 15 nights/month.~* Minimum average of 15 Periodic Limb Movements during Sleep per hour (measured using actigraphy).~Exclusion criteria:~* Secondary RLS~* Primary sleep disorder~* Sleep apnea~* Have any medical conditions that may impact efficacy assessments or that may present a safety concern.~* Pregnant or lactating or women of child-bearing potential who are not practicing an acceptable method of birth control.~* Use of any prohibited medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK1838262:placebo (Type: OTHER): GSK1838262 extended release tablets for Treatment Period 1 followed by Placebo for Treatment Period 2
- Placebo:GSK1838262 (Type: OTHER): Placebo for Treatment Period 1 followed by GSK1838262 for Treatment Period 2

Based on this trial design, predict the completion outcome and termination type (if applicable).